Drug intelligence / Profile preview

anti-miR-7

Development stage
Preclinical
Lead developer
Thermo Fisher Scientific
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Parenteral
01

Overview

anti-miR-7 is a synthetic antisense oligonucleotide designed to specifically target and inhibit the function of microRNA-7 (miR-7). miR-7 is a highly conserved microRNA that is frequently dysregulated in various pathological conditions, particularly in oncology where it can act as an oncomir by promoting cell proliferation, migration, and invasion through the regulation of targets such as EGFR, IRS-1, and Raf-1. In the context of endometrial cancer, anti-miR-7 has demonstrated the ability to significantly inhibit the migration and invasion of invasive cell lines like HEC-1A in vitro. These molecules typically function by binding to the mature miR-7 sequence via complementary base-pairing, thereby sequestering the miRNA and preventing its interaction with target messenger RNAs. While primarily utilized as a research-use-only (RUO) tool for functional genomics, miR-7 inhibitors are being explored as potential therapeutic candidates for the treatment of advanced-stage cancers and other miR-7-associated diseases.

Other names
miR-7 inhibitormiR7 inhibitormiR 7 inhibitorantagomir-7antagomir7antagomir 7anti-microRNA-7anti-microRNA7anti-microRNA 7
02

Targets

miR-7 (MicroRNA 7)

Beyond the preview

Go deeper on anti-miR-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-miR-7.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call